Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Escitalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Citalopram SCHEMBL13235283 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL29494157 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| (R)-Citalopram SCHEMBL29414626 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL29358316 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL3858802 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL946 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL522164 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1118 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL21820669 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1286979 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24051 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746863-A1 | ENDOXIFEN COMPOSITIONS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF | Atossa Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-122060656-A | Engineering strain for efficiently producing ectoin by polysaccharide co-utilization and fermentation process | 南京工业大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739303-A2 | MDMA ENANTIOMER COMPOSITIONS AND METHODS FOR MODULATING AGGRESSION RESPONSE | EmpathBio, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20020160050-A1 | Melt granulated composition and modified release dosage form prepared from said composition | H. LUNDBECK A/S (DK) | 2002-10-31 | — | — | US | claimed |
| EP-1237553-A2 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT 2C? ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST | H. LUNDBECK A/S (DK) | 2002-09-11 | — | — | EP | claimed |
| US-20020103249-A1 | Combination of a serotonin reuptake inhibitor and irindalone | H. LUNDBECK A/S | 2002-08-01 | — | — | US | claimed |
| EP-1220658-A1 | MELT GRANULATED COMPOSITION AND MODIFIED RELEASE DOSAGE FORM PREPARED FROM SAID COMPOSITION | H. Lundbeck A/S (DK) | 2002-07-10 | — | — | EP | claimed |
| US-20020086899-A1 | Treatment of neurotic disorders | H. LUNDBECK A/S (DK) | 2002-07-04 | — | — | US | claimed |
| EP-1200081-A1 | TREATMENT OF NEUROTIC DISORDERS | H. LUNDBECK A/S (DK) | 2002-05-02 | — | — | EP | claimed |
| WO-2001041766-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND IRINDALONE | H. LUNDBECK A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| WO-2001041701-A2 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST | H. LUNDBECK A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| WO-2001022941-A1 | MELT GRANULATED COMPOSITION AND MODIFIED RELEASE DOSAGE FORM PREPARED FROM SAID COMPOSITION | H. LUNDBECK A/S (DK) | 2001-04-05 | — | — | WO | claimed |
| WO-2001003694-A1 | TREATMENT OF NEUROTIC DISORDERS | H. LUNDBECK A/S (DK) | 2001-01-18 | — | — | WO | claimed |